Erudio Healtherudio.com
Sponsor
Incyte trials: what clinicians said in public
HCP commentary reports on 2 clinical trials sponsored by Incyte: DAWN-303 and INCB161734-101. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 17 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Incyte Corporation). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| INCB161734-101 NCT06179160 · Incyte Corporation | KRAS G12D-mutated advanced or metastatic solid tumors | Phase 1 | 32 | 18 | Focused | Nov 20, 2026 | Preview |
| DAWN-303 NCT07522073 · Incyte Corporation | previously untreated KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma | Phase 3 | 58 | 15 | Focused | Oct 29, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| frontMIND NCT04824092 · Incyte Corporation DeepView → | newly diagnosed high-intermediate and high-risk DLBCL | Phase 3 | Deep | View | |||
| inMIND NCT04680052 · Incyte Corporation DeepView → | relapsed/refractory follicular or marginal zone lymphoma | Phase 3 | Deep | View | |||
| FIGHT-302 NCT03656536 · Incyte Corporation DeepView → | first-line advanced cholangiocarcinoma with FGFR2 rearrangements | Phase 3 | Deep | View | |||
| FIGHT-202 NCT02924376 · Incyte Corporation DeepView → | previously treated locally advanced or metastatic cholangiocarcinoma | Phase 2 | Deep | View | |||
| InterAACT 2 NCT04472429 · Incyte Corporation DeepView → | locally recurrent or metastatic squamous cell anal carcinoma | Phase 3 | Deep | View | |||
| FIGHT-101 NCT02393248 · Incyte Corporation DeepView → | advanced malignancies | Phase 1/Phase 2 | Deep | View | |||
| AALL1521 NCT02723994 · Incyte Corporation FocusedView → | Not given | Phase 2 | Focused | View | |||
| FIGHT-201 NCT02872714 · Incyte Corporation FocusedView → | metastatic or unresectable urothelial carcinoma with FGF/FGFR alterations | Phase 2 | Focused | View | |||
| FIGHT-207 NCT03822117 · Incyte Corporation FocusedView → | previously treated solid tumors with activating FGFR1-FGFR3 alterations | Phase 2 | Focused | View | |||
| CITADEL-204 NCT03144674 · Incyte Corporation FocusedView → | relapsed or refractory marginal zone lymphoma | Phase 2 | Focused | View | |||
| CITADEL-205 NCT03235544 · Incyte Corporation FocusedView → | relapsed or refractory mantle cell lymphoma | Phase 2 | Focused | View | |||
| LIMBER NCT04279847 · Incyte Corporation FocusedView → | Not given | Phase 1 | Focused | View | |||
| LIMBER-304 NCT04551053 · Incyte Corporation FocusedView → | myelofibrosis with suboptimal response to ruxolitinib | Phase 3 | Focused | View | |||
| FIGHT-203 NCT03011372 · Incyte Corporation FocusedView → | myeloid/lymphoid neoplasms with FGFR1 rearrangement | Phase 2 | Focused | View | |||
| NCT05936359 NCT05936359 · Incyte Corporation FocusedView → | CALR-mutated myeloproliferative neoplasms | Phase 1 | Focused | View | |||
| NCT06034002 NCT06034002 · Incyte Corporation FocusedView → | myeloproliferative neoplasms with CALR mutation | Phase 1 | Focused | View | |||
| MAESTRA 3 NCT07797283 · Incyte Corporation FocusedView → | advanced epithelial ovarian cancer overexpressing cyclin E1 | Phase 3 | Focused | View | |||